Scholar Rock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Scholar Rock 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRRK

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. 

CEO
David L. Hallal
CEODavid L. Hallal
Employees
196
Employees196
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2012
Founded2012
Employees
196
Employees196

SRRK Key Statistics

Market cap
4.74B
Market cap4.74B
Price-Earnings ratio
-13.46
Price-Earnings ratio-13.46
Dividend yield
Dividend yield
Average volume
1.07M
Average volume1.07M
High today
$46.74
High today$46.74
Low today
$43.19
Low today$43.19
Open price
$43.57
Open price$43.57
Volume
801.44K
Volume801.44K
52 Week high
$48.28
52 Week high$48.28
52 Week low
$22.71
52 Week low$22.71

Stock Snapshot

The current Scholar Rock(SRRK) stock price is $46.26, with a market capitalization of 4.74B. The stock trades at a price-to-earnings (P/E) ratio of -13.46.

During the trading session on 2026-01-14, Scholar Rock(SRRK) shares reached a daily high of $46.74 and a low of $43.19. At a current price of $46.26, the stock is +7.1% higher than the low and still -1.0% under the high.

Trading activity shows a volume of 801.44K, compared to an average daily volume of 1.07M.

The stock's 52-week range extends from a low of $22.71 to a high of $48.28.

The stock's 52-week range extends from a low of $22.71 to a high of $48.28.

SRRK News

TipRanks 2d
Scholar Rock Details 2026 Strategy and Regulatory Priorities

Claim 70% Off TipRanks Premium Scholar Rock Holding ( (SRRK) ) has provided an announcement. On January 12, 2026, Scholar Rock issued a corporate update outli...

TipRanks 5d
Scholar Rock initiated with a Buy at Citi

Citi initiated coverage of Scholar Rock (SRRK) with a Buy rating and $55 price target The firm believes concerns over the company’s manufacturing on apitegromab...

TipRanks 5d
Buy/High Risk: Apitegromab’s Differentiated SMA Profile and Expanding Neuromuscular Upside Support Significant Re-Rating Potential

Geoff Meacham, an analyst from Citi, has initiated a new Buy rating on Scholar Rock Holding (SRRK). Claim 70% Off TipRanks Premium Unlock hedge fund-level data...

Analyst ratings

100%

of 16 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own SRRK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .